# Convergence Check 77 - Survivor-Map Branch Closure

Timestamp: 2026-05-28 09:04 CEST

## Question

After closing EPHX2, ABTB2, CD44/SPP1, HLA-II rows, FPR2/ANXA1, and CD300, does
the Wave110/Wave91/Wave95 survivor-map family still contain an actionable route?

## Evidence

- Wave116 now reports `NO_OPEN_ROUTE_AFTER_CLOSURE_RERANK`.
- `n_actionable_routes=0`.
- The remaining high-scoring open rows are all explicit `NO_GO` or blocked rows
  such as eicosanoid receptors, TREM1, IRF1, IFI30, CTSB, retinoid/VDR/RXR,
  IL7R, RFX5, PPAR/LXR/RXR, and MED16.

## Decision

Close this survivor-map branch.

## Scope

This is not global exhaustion. It closes only the route family derived from
Wave110/Wave91/Wave95 after repeated local closure audits.

## Next Forcing Question

Launch a fresh breadth-first target-class scan from the full local evidence
base, excluding closure-ledger terms and requiring independent support from at
least two non-overlapping evidence channels before a route can be reopened.
